Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02101788 · MORE INFO

Limitations, agreements, and source contact

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer · Source last updated 2026-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
LTE60
restrictive Agreement
true
limitations And Caveats
description
The pERK expression analysis is still under development, and will not be available for approximately 2 - 3 years.
point Of Contact
email
linda.gedeon@roswellpark.org
organization
NRG Oncology
phone
716-845-1169
title
Linda Gedeon for Austin Miller, PhD
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
LTE60
restrictive Agreement
true
limitations And Caveats
description
The pERK expression analysis is still under development, and will not be available for approximately 2 - 3 years.
point Of Contact
email
linda.gedeon@roswellpark.org
organization
NRG Oncology
phone
716-845-1169
title
Linda Gedeon for Austin Miller, PhD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice